AC
XFOR icon

Armistice Capital’s X4 Pharmaceuticals XFOR Stock Holding History

Armistice Capital’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-64,533
Closed -$1.62M – 419
2023
Q4 		$1.62M Sell
64,533
-14,000
-18% -$340K 0.02% 161
2023
Q3 		$2.57M Sell
78,533
-20,667
-21% -$901K 0.04% 129
2023
Q2 		$5.77M Buy
+99,200
New +$5.1M 0.08% 115

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Armistice Capital's XFOR Position: Q1 2024 in Review

Armistice Capital sold out of X4 Pharmaceuticals (XFOR) in Q1 2024, closing a stake of 64,533 shares — an estimated $1.62M sold.

Armistice Capital first reported a position in XFOR in Q2 2023 and held it in 3 quarters. The position peaked at $5.77M in Q2 2023. 96 funds tracked by Wall St. Rank hold XFOR as of Q1 2024.

  • Armistice Capital reported no remaining X4 Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 64,533 X4 Pharmaceuticals shares in Q1 2024, an estimated $1.62M.
  • Armistice Capital first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Armistice Capital's X4 Pharmaceuticals position peaked at $5.77M in Q2 2023.
  • 96 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.